Study to Evaluate IMGS-001 Treatment in Patients With Relapsed or Refractory Advanced Solid Tumors
NCT06014502 is a phase 1 interventional trial sponsored by ImmunoGenesis. As of 21 Nov 2026, it is recruiting participants. It studies IMGS-001 in Solid Tumor. The registry lists an enrollment of 105 participants at 13 sites in 1 country. The registry lists a start date of 7 Sept 2023 and a primary completion date of 31 Dec 2027. One of its registered investigators has a FindMyKOL profile.
Key facts
Registry attributes as recorded on the ClinicalTrials.gov study record.
| Field | Value |
|---|---|
| Registry ID | NCT06014502 |
| Status | Recruiting |
| Phase | Phase 1 |
| Study type | Interventional trial |
| Lead sponsor | ImmunoGenesis |
| Enrollment | 105 |
| Registered sites | 13 |
| Countries | 1 |
| Conditions | Solid Tumor |
| Drugs | IMGS-001 |
| Start | 7 Sept 2023 |
| Primary completion | 31 Dec 2027 |
| Study completion | 31 Dec 2028 |
| Last update posted | 4 Sept 2026 |
Registered summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
No overall officials are registered on this study record. Site-level investigators, where published, appear with their sites below. Why? →
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
13 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Banner Md Anderson Cancer Center
Gilbert
Madappa Kundranda, MDRecruiting
- Uc Irvine
Orange
Victoria Villaflor, MDRecruiting - Sarcoma Oncology Center
Santa Monica
Neal S. Chawla, MDRecruiting
- Moffitt Cancer Center
Tampa
Robin Park, MDRecruiting
- St. Elizabeth Healthcare
Edgewood
Daniel Flora, MDRecruiting
- Ochsner Clinic Foundation
New Orleans
Daniel Johnson, MDRecruiting
- Washu
St Louis
Brendan J Knapp, MDRecruiting
- Fox Chase Cancer Center
Philadelphia
Parth A Desai, MBBS, MDRecruiting - Upmc Hillman Cancer Center
Pittsburgh
Diwakar Davar, MBBS, MScRecruiting
- Md Anderson Cancer Center
Houston
David S. Hong, MDRecruiting - Next Dallas
Irving
Shiraj Sen, MDRecruiting - Texas Oncology
Tyler
Donald Richards, MD, PhDRecruiting
- Virginia Oncology Associates
Norfolk
Jedrzej Wykretowicz, MD, PhDRecruiting
United States, by state
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Questions about NCT06014502
Each answer restates registry values shown on this page.
What is NCT06014502?
NCT06014502 is a phase 1 interventional trial sponsored by ImmunoGenesis. It studies IMGS-001 in Solid Tumor.
Is NCT06014502 recruiting?
As of 21 Nov 2026, it is recruiting participants. 13 of its 13 sites list their own status as recruiting.
Where does NCT06014502 run?
The registry lists 13 sites in 1 country. Every site with a stated country is in one country: United States.
Which drugs does NCT06014502 study?
The registered drug and biological interventions are IMGS-001.
When is NCT06014502 expected to complete?
The registry lists a primary completion date of 31 Dec 2027 and a study completion date of 31 Dec 2028. The sponsor last updated the record on 4 Sept 2026.
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.